Payment overview · 2025
General Payments
$1,841.11
108 reported records · 27 companies
Healthcare provider profile · identity verified
Damon Daniels, MD,MPH
Allopathic & Osteopathic Physicians|Family Medicine · COLUMBIA, SC · NPI 1235104464
Verified facts
What the public records show
CMS Open Payments records show Damon Daniels, MD,MPH received $1,841.11 in general payments during 2025 across 108 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $310.73 | 16.9% | 18 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $185.86 | 10.1% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $176.02 | 9.6% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $162.83 | 8.8% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $127.50 | 6.9% | 8 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $114.30 | 6.2% | 6 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $104.52 | 5.7% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $74.25 | 4.0% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $67.32 | 3.7% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.96 | 3.1% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $46.80 | 2.5% | 3 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $38.63 | 2.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $37.97 | 2.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.97 | 1.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.71 | 1.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.13 | 1.9% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $29.24 | 1.6% | 2 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $25.81 | 1.4% | 1 | 2025 |
| CorVista Health, Inc. | Unresolved — no canonical attribution shown | $25.40 | 1.4% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.26 | 1.2% | 1 | 2025 |
| Emmaus Medical, Inc. | Unresolved — no canonical attribution shown | $20.81 | 1.1% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $20.13 | 1.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.21 | 1.0% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $18.98 | 1.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.19 | 0.9% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $17.00 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.58 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,808.84 | 107 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $185.86 | 14 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $176.02 | 12 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $170.85 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $130.86 | 7 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $114.30 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $112.15 | 6 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $104.52 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $93.71 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $93.71 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $93.59 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $93.59 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $84.52 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $74.25 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $67.32 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $66.51 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $66.51 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $66.51 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $56.96 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $46.80 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.98 | 2 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $38.63 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $37.97 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $35.97 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.71 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.13 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $33.79 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $29.24 | 2 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $25.81 | 1 | 2025 |
Source payment records
|
|||||
| CorVista System Normalized: corvista system |
Device | CorVista Health, Inc. | $25.40 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| Endari Normalized: endari |
Drug | Emmaus Medical, Inc. | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $2.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 131 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 91 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 44 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 100 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 16 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
131 | 29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
100 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
90 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 15 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 445 | 127 |
| Amlodipine Besylate | Amlodipine Besylate | 423 | 126 |
| Atorvastatin Calcium | Atorvastatin Calcium | 327 | 99 |
| Montelukast Sodium | Montelukast Sodium | 323 | 106 |
| Metoprolol Succinate | Metoprolol Succinate | 192 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 149 | 57 |
| Losartan Potassium | Losartan Potassium | 148 | 42 |
| Furosemide | Furosemide | 145 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 40 |
| Farxiga | Dapagliflozin Propanediol | 131 | 29 |
| Famotidine | Famotidine | 126 | 38 |
| Metformin Hcl Er | Metformin Hcl | 124 | 41 |
| Allopurinol | Allopurinol | 117 | 33 |
| Gabapentin | Gabapentin | 108 | 38 |
| Potassium Chloride | Potassium Chloride | 108 | 28 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 108 | 26 |
| Januvia | Sitagliptin Phosphate | 105 | 22 |
| Levothyroxine Sodium | Levothyroxine Sodium | 105 | 26 |
| Lisinopril | Lisinopril | 104 | 30 |
| Omeprazole | Omeprazole | 102 | 28 |
| Metformin Hcl | Metformin Hcl | 101 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 28 |
| Ozempic | Semaglutide | 100 | 19 |
| Ezetimibe | Ezetimibe | 98 | 30 |
| Finasteride | Finasteride | 94 | 33 |
| Jardiance | Empagliflozin | 91 | 22 |
| Eliquis | Apixaban | 90 | 27 |
| Valsartan | Valsartan | 87 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 81 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 77 | 14 |
| Myrbetriq | Mirabegron | 72 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | 20 |
| Tramadol Hcl | Tramadol Hcl | 70 | 21 |
| Memantine Hcl | Memantine Hcl | 66 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 17 |
| Glipizide Er | Glipizide | 58 | 19 |
| Mounjaro | Tirzepatide | 58 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 54 | 21 |
| Meloxicam | Meloxicam | 53 | 17 |
| Spironolactone | Spironolactone | 53 | 14 |
| Carvedilol | Carvedilol | 52 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 16 |
| Nifedipine Er | Nifedipine | 51 | 16 |
| Alendronate Sodium | Alendronate Sodium | 50 | 15 |
| Mirtazapine | Mirtazapine | 48 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 20 |
| Ibuprofen | Ibuprofen | 45 | suppressed |
| Linzess | Linaclotide | 44 | 15 |
| Pregabalin | Pregabalin | 44 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 43 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 42 | 14 |
| Prednisone | Prednisone | 42 | 34 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 39 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 15 |
| Trazodone Hcl | Trazodone Hcl | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 13 |
| Diazepam | Diazepam | 36 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Simvastatin | Simvastatin | 35 | 13 |
| Alprazolam | Alprazolam | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 12 |
| Trulicity | Dulaglutide | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 32 | 12 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 31 | 12 |
| Lorazepam | Lorazepam | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Livalo | Pitavastatin Calcium | 25 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 25 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 24 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 19 |
| Glimepiride | Glimepiride | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 13 |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,841.11 · 108 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, CorVista System, Endari, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, ImmunoCAP, JARDIANCE, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Kerendia, Korlym, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, Paradise Ultrasound Renal Denervation System, QULIPTA, REPATHA, Rybelsus, SPRAVATO, TRELEGY ELLIPTA, TZIELD, UBRELVY, VOQUEZNA, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error